One-year results of visual response following intravitreal novel anti-VEGF injection for diabetic macular edema in a Latino population.

ABSTRACT:

Background

Diabetic macular edema (DME) is a leading cause of vision impairment. This study evaluated the effects of multiple anti-VEGF intravitreal injections, including a novel anti-VEGF PRO-169, on best-corrected visual acuity (BCVA) and central macular thickness (CMT) in Latino patients with DME.

Methods

This is a multicenter, drug-agnostic interim analysis. Patients were randomized 1:1 to receive monthly injections for four months after a pro re nata intravitreal injection of either PRO-169 or ranibizumab over a one-year period.

Results

A total of 278 eyes with DME were analyzed. The average age of the participants was 62.1 ± 7.4 years, with diabetes diagnosed at an average of 16.7 ± 8.4 years and DME detected 1.2 ± 1.6 years later. By week 48, patients with an i

SUBMITTER: Salcedo-Villanueva G 

PROVIDER: S-EPMC12315349 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature